Cite
HARVARD Citation
Augustin, M. et al. (2022). Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany. Journal of dermatological treatment. pp. 976-982. [Online].